18 peptides

Best Peptides for Weight Loss

Research-backed peptides for weight management, fat loss, and metabolic optimization. From GLP-1 receptor agonists like Semaglutide and Tirzepatide to NNMT inhibitors like 5-Amino-1MQ, explore the most studied peptides for body composition.

By Peptide Assistant Editorial Team · ·

Read the full weight loss guide

5-Amino-1MQ

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme strongly linked to obesity and metabolic dysfunction. By selectively blocking NNMT, it raises intracellular NAD+ levels and, in obese mice, shrinks fat cells without suppressing appetite or stimulating the central nervous system. It has emerged as one of the most promising anti-obesity compounds in the peptide-adjacent research space, attracting attention for its unique non-stimulant mechanism of action.

2 variants$40–$169

Adipotide (FTTP)

Adipotide (FTTP — Fat-Targeted Proapoptotic Peptide) is a peptidomimetic that selectively destroys the blood vessels feeding white adipose tissue, causing targeted fat cell death through vascular disruption. Originally developed at MD Anderson Cancer Center using cancer drug delivery technology repurposed for obesity, it produced dramatic fat loss in monkeys, between 7.4% and 14.7% of body weight over 28 days. However, it carries significant renal risks and is considered one of the more aggressive fat loss compounds in the research peptide space.

2 variants$39.99–$75

AICAR

AICAR (5-aminoimidazole-4-carboxamide ribonucleoside, also known as Acadesine) is a potent AMP-activated protein kinase (AMPK) activator that mimics the metabolic effects of endurance exercise at the cellular level. Originally developed as a cardioprotective agent for coronary bypass surgery, it gained widespread attention after a landmark 2008 study showed it improved running endurance by 44% in sedentary mice. Prohibited by the World Anti-Doping Agency as a metabolic modulator, it remains one of the most studied exercise-mimetic compounds in metabolic research.

1 variant$50

AOD-9604

AOD-9604 is a modified 16-amino-acid fragment of human growth hormone (corresponding to amino acids 176–191 of the hGH sequence) that retains the potent fat-metabolizing properties of growth hormone while completely lacking its growth-promoting, diabetogenic, and IGF-1-elevating effects. Developed at Monash University in Australia, it stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from full-length GH, making it one of the most targeted and well-characterized anti-obesity peptides available. It is not approved by any regulator for any use, and its cartilage-regenerative properties come from animal work.

3 variants$30–$80

BAM-15

BAM-15 is a next-generation mitochondrial uncoupling agent that dissipates the proton gradient across the inner mitochondrial membrane, converting stored energy directly into heat rather than ATP. Unlike the notorious uncoupler DNP (2,4-dinitrophenol), BAM-15 selectively targets mitochondrial membranes without depolarizing the plasma membrane, providing a dramatically wider therapeutic window. In mice, it decreases body fat mass, improves insulin sensitivity and lowers liver fat, without affecting food intake, lean mass or body temperature. In a mouse model of steatohepatitis it reduced liver fat but did not change fibrosis.

2 variants$155–$225

Cagrilintide

Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk that reduces appetite and food intake by activating amylin receptors in the brainstem — a satiety pathway distinct from and complementary to GLP-1 signaling. When combined with semaglutide in the CagriSema formulation, it produced a mean 20.4% body weight reduction at 68 weeks in the Phase III REDEFINE 1 trial. As a standalone agent, cagrilintide produces meaningful weight loss that validates amylin as a major therapeutic target in obesity.

2 variants$100–$155

Cagri-Sema Blend

The CagriSema blend combines cagrilintide (a long-acting amylin analog) with semaglutide (a GLP-1 receptor agonist) in a single formulation, targeting two anatomically and mechanistically distinct satiety pathways for unprecedented weight loss efficacy. This dual-mechanism approach — brainstem amylin signaling plus hypothalamic GLP-1 signaling — produced a mean 20.4% body weight reduction at 68 weeks in the Phase III REDEFINE 1 trial, compared with 3.0% on placebo.

1 variant$149

L-Carnitine

L-Carnitine is a naturally occurring amino acid derivative essential for mitochondrial fatty acid transport. It shuttles long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation — making it critical for fat metabolism and cellular energy production. Injectable L-Carnitine is used for enhanced fat burning, exercise performance, and metabolic support.

3 variants$35–$200

Mazdutide

Mazdutide (LY3305677/IBI362) is a novel dual GLP-1/glucagon receptor agonist developed by Eli Lilly (licensed to Innovent Biologics for China). Unlike tirzepatide (which targets GLP-1/GIP), mazdutide adds glucagon receptor agonism to enhance energy expenditure and fat oxidation alongside appetite suppression. It represents the next frontier in metabolic peptide therapeutics.

1 variant$100

Methylene Blue

Methylene blue is a synthetic phenothiazine dye that has been repurposed as a mitochondrial enhancer and neuroprotective agent. Originally used as a medical dye and antimalarial, it functions as an alternative electron carrier in the mitochondrial electron transport chain, enhancing cellular energy production and reducing oxidative stress. It is one of the oldest synthetic drugs in medicine, with a history dating back to 1876.

2 variants$24.99–$30.99

O-304 (ATX-304)

O-304 is a novel small-molecule AMPK activator developed by Betagenon AB that directly activates AMPK by preventing its dephosphorylation. Unlike indirect AMPK activators, O-304 maintains AMPK in its active phosphorylated state, producing exercise-mimetic and glucose-lowering effects. It has completed Phase IIa clinical trials for type 2 diabetes with promising results.

1 variant$200

Retatrutide

Retatrutide (LY3437943) is a novel triple-agonist peptide developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors — the first 'triagonist' in its class. In Phase II clinical trials, retatrutide produced unprecedented weight loss of up to 24.2% of body weight at 48 weeks, a larger average loss than semaglutide or tirzepatide produced in their own trials (no head-to-head comparison has been published). It represents the cutting edge of incretin-based metabolic therapy and is currently in Phase III trials for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH/NASH).

5 variants$135–$330

Retatrutide + Cagrilintide Blend

Reta-Cagri Blend combines retatrutide, a triple-agonist GLP-1/GIP/glucagon receptor peptide, with cagrilintide, a long-acting amylin analog. This combination targets multiple metabolic pathways simultaneously — appetite suppression, insulin sensitization, glucagon-mediated fat oxidation, and gastric emptying regulation. The blend represents a next-generation approach to obesity pharmacotherapy, leveraging synergistic mechanisms that individually have shown dramatic weight loss in clinical trials.

1 variant$129.99

Semaglutide

Semaglutide is a GLP-1 receptor agonist that has revolutionized the treatment of type 2 diabetes and obesity. FDA-approved as Ozempic (injectable, diabetes), Wegovy (injectable, obesity), and Rybelsus (oral, diabetes), it is the most widely prescribed and clinically validated peptide for metabolic disease. Semaglutide produces unprecedented weight loss of 15–17% in clinical trials and has demonstrated cardiovascular, renal, and potentially neuroprotective benefits beyond glycemic control.

5 variants$43–$300

SLU-PP-332

SLU-PP-332 is a small-molecule agonist of the estrogen-related receptor (ERR) family, particularly ERRα, ERRβ, and ERRγ. Dubbed an 'exercise mimetic,' it activates the same transcriptional programs induced by endurance exercise — mitochondrial biogenesis, fatty acid oxidation, and oxidative muscle fiber gene expression. In preclinical studies, it dramatically improved exercise endurance and fatigue resistance without physical training.

4 variants$89.99–$799

Survodutide

Survodutide (BI 456906) is a dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim. Unlike tirzepatide (GLP-1/GIP), survodutide pairs GLP-1 receptor agonism with glucagon receptor agonism, specifically targeting hepatic fat metabolism and energy expenditure. It has shown remarkable efficacy for both obesity and MASH (metabolic dysfunction-associated steatohepatitis), with Phase II data demonstrating about 15% weight loss at the highest dose (13% at 76 weeks in the later Phase III trial) and substantial liver fat reduction.

1 variant$110

Tesofensine

Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, and dopamine) originally developed for Alzheimer's and Parkinson's disease that was repurposed for obesity treatment after clinical trials revealed dramatic weight loss as a side effect. It is one of the most potent appetite suppressants studied in clinical trials, with Phase II data showing about 9% weight loss at 0.5 mg and 10.6% at 1.0 mg over 24 weeks, roughly twice what drugs approved at the time achieved.

1 variant$155

Tirzepatide

Tirzepatide is a first-in-class dual GLP-1/GIP receptor agonist that has redefined the treatment landscape for type 2 diabetes and obesity. FDA-approved as Mounjaro (diabetes, 2022) and Zepbound (obesity, 2023), tirzepatide produces some of the largest weight loss seen with an approved medication — about 21% on average at the highest dose in the SURMOUNT-1 trial. Its dual incretin mechanism activates both GLP-1 and GIP receptors, producing superior metabolic effects compared to GLP-1-only agonists like semaglutide. Tirzepatide has also shown groundbreaking results in obstructive sleep apnea, heart failure with preserved ejection fraction, and MASH.

4 variants$140–$480

Track Your Weight Loss Protocol

Log your doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free

Explore Other Categories